Medical Device Procurement Is Stuck in the Past — and It's Costing Hospitals Real Money

Most hospitals are buying medical devices the wrong way. The industry has evolved—but procurement strategies haven't.

I'm a procurement manager at a 400-bed community hospital. I've managed our medical device budget ($3.2M annually) for 8 years. I've negotiated with 60+ vendors and documented every purchase in our cost tracking system. In that time, I've watched the medical device landscape transform. But many of the hospitals I network with still evaluate equipment the same way they did in 2015.

The vendor failure in March 2023 changed how I think about device procurement. We'd bought a batch of supposedly 'equivalent' ultrasound probes from a lower-cost supplier to replace our stock. The initial quote was great—14% cheaper than our usual vendor. Not great, not terrible. Serviceable. Then the first probe failed after 65 uses. The warranty replacement took three weeks. The service cost, the downtime, the rescheduling... that cheap item cost us $4,800 in hidden expenses. A lesson learned the hard way.

Why does this matter? Because the medical device industry is not standing still. Technologies that were best practice in 2020 may not apply in 2025. If your procurement checklist hasn't changed, you're making decisions based on an outdated map.

What I've learned about how the device industry actually evolved

1. Price per unit is meaningless. Total cost of ownership is the only number that counts.

I've become obsessed with TCO—total cost of ownership. When we were evaluating hemodynamic monitoring platforms a few years ago, the initial quote from Edwards Lifesciences was significantly higher than a rival system. The numbers said go with the cheaper option. My gut said stick with Edwards. Went with my gut. Later learned the rival platform needed additional modules to integrate with our existing ICU infrastructure. Those modules weren't in the original quote. The Edwards system, on the other hand, included the interfaces we needed and offered a clearer upgrade path.

That's a 28% difference hidden in fine print. In my opinion, TCO is the only defensible way to evaluate edwards lifesciences medical devices or any capital equipment. But TCO doesn't appear in most hospital purchase orders.

2. Devices are no longer point solutions—they're platforms.

The biggest shift I've seen is the transition from standalone tools to integrated platforms. Edwards Lifesciences, for example, isn't just selling a monitor anymore. They sell a system that connects hemodynamic data across the ICU, which reduces the need for separate equipment and cuts training time for nurses. I checked their current product line on the edwards lifesciences official website while preparing our budget last year. It's a different company than the one I first encountered in 2017.

This same shift affects even the simplest tools. Look at surgical staplers. The manual stapler we used a decade ago has evolved into powered, smart staplers with tissue-sensing technology. Is the new version more expensive upfront? Absolutely. But in high-volume ORs, the reduction in staple-line leaks and reoperations pays for the cost difference many times over. As I told our CFO, if you're still buying staplers based on the per-unit price, you're ignoring the fact that the product category has transformed.

The fundamentals of what the device does haven't changed—you still need to close tissue. But the execution has transformed. That's what 'industry in evolution' really means.

3. Infection control is now a device design feature—not just a cleaning protocol.

When someone asks 'what is infection control' in the context of medical devices, they usually think of surface disinfection and sterilization. That's outdated thinking. Modern infection control starts with design.

Take ultrasound machines. The probe is a classic vector for cross-contamination if not handled correctly. Some manufacturers now offer probes with sealed, disinfection-friendly casings and fewer crevices where pathogens can hide. Choosing an ultrasound machine without evaluating its infection control design is, in my view, a clinical risk. We learned this ourselves when we did a 90-day trial of two different ultrasound systems—one had a cable management design that made contamination control significantly easier. That feature wasn't in the spec sheet, but it showed up in our infection prevention team's review.

The same logic applies to surgical staplers with ergonomic triggers that reduce sharps injuries, and to monitoring systems designed with fewer touchpoints. In 2025, infection control isn't just about cleaning after use. It's about how many germs the device can hide in the first place.

4. Technology cycles are shorter than hospital depreciation schedules.

Here's the uncomfortable truth: most hospitals keep capital equipment for 7-10 years. But product lifecycles for cutting-edge devices are now closer to 4-5 years. If you buy the latest imaging or hemodynamic system today, you can expect a meaningful upgrade within five years. That's not a reason to delay purchasing—it's a reason to negotiate upgrade paths and software guarantees into your contract.

I'm not saying the old way of buying equipment—based on a single quote, a clinical champion, and a three-year service contract—was entirely wrong. To be fair, that approach did deliver consistent results in a simpler era. But the industry has changed. Device complexity has grown. The stakes are higher. The old rules don't hold up.

Granted, adopting a TCO-first approach requires more upfront work. You have to create a spreadsheet that tracks maintenance, consumables, training, infection rates, and resale value. It's time-consuming. But after tracking 300+ orders over six years in our procurement system, I found that 68% of our budget overruns came from ignoring these 'soft' costs. We implemented a mandatory TCO worksheet for all capital purchases, and over the next two years, we cut overruns by 21%.

The question isn't whether your initial bid is lower. The question is whether the device will still perform—and still be cost-effective—in year five.

So here's my challenge to every hospital procurement department: sit down and ask yourself if your evaluation criteria have evolved as fast as the industry. Check your current contract terms. Ask suppliers about upgrade paths. Demand infection control data. Calculate TCO, not just PO. The industry is moving forward either way. You can either keep using a map from 2015, or you can update it.

The medical device industry has evolved. It's time procurement caught up.